Advertisement
Advertisement
Dr. Axe Wire · Study decoded · health
Daily Obesity Pill Orforglipron Cut Bodyweight Up to 8.7% in Japanese Phase 3 Trial
A phase 3 trial found an investigational daily pill outperformed placebo for weight loss in Japanese adults with obesity.
At a glance
- What they found: More than half on the two higher doses lost at least 5% of weight, versus 15% on placebo.
- Who was studied: 238 Japanese adults with obesity, 61% male, average age 54, randomly assigned 1:1:1:1.
An investigational oral GLP-1 drug produced up to an 8.7% reduction in bodyweight over 72 weeks in Japanese adults with obesity, according to a phase 3 trial published October 30, 2026 in The Lancet Diabetes & Endocrinology.
8.7%max weight loss
0.6%with placebo
72-weektrial
238adults studied
A phase 3 trial called ATTAIN-J randomly assigned 238 Japanese adults with obesity (61% male, 39% female, average age 54) to once-daily oral orforglipron at 6 mg, 12 mg or 36 mg, or to placebo, for 72 weeks. Average bodyweight change was -5.9% with the 6 mg dose, -8.7% with 12 mg and -7.9% with 36 mg, compared with -0.6% with placebo. At least 5% bodyweight loss occurred in 45.6% of the 6 mg group, 60.8% of the 12 mg group and 58.8% of the 36 mg group, versus 15.2% on placebo. Of the 238 randomized, 90% completed the study.
Adverse events with orforglipron were mostly mild-to-moderate digestive symptoms. Discontinuation due to nausea occurred in 2% (6 mg), 2% (12 mg) and 8% (36 mg), versus none on placebo; discontinuation due to vomiting occurred in 0% (6 mg), 4% (12 mg) and 2% (36 mg), versus none on placebo.
Advertisement
Orforglipron is a small-molecule, non-peptide pill version of GLP-1 receptor agonists, a drug class usually given by injection that works on gut-brain signaling to increase fullness and slow digestion. The authors concluded the pill produced statistically superior bodyweight reduction versus placebo, with a safety profile consistent with other GLP-1 drugs. Taken orally, it could make this drug class easier to produce and access if approved.
Bodyweight Change at 72 Weeks by Dose
This trial compared the drug only with placebo in one country over 72 weeks, so it does not show how orforglipron performs against existing injectable GLP-1 drugs, what happens with longer use, or whether weight returns after stopping.
Dr. Axe’s Take
Orforglipron isn't approved yet, so nothing here changes what's at the pharmacy today. But the pattern holds for approved GLP-1 medicines too: they work on appetite and fullness signals, not on the muscle loss or nutrient gaps that rapid weight loss can bring. I pair these medicines with a whole-food, high-protein diet, fiber from vegetables and legumes, and resistance training to protect muscle. Many people do well on a much lower dose of approved GLP-1 drugs, often 10 to 20% of the labeled dose, worked out with the prescribing doctor instead of adjusting on their own. Watch for nausea and vomiting, the most common reasons people stopped the drug here.
— Dr. AxeTake the Metabolic Health Quiz →
Study summary
- Who
- 238 Japanese adults with obesity, 61% male, average age 54, randomly assigned 1:1:1:1.
- Design
- Double-blind, randomized, placebo-controlled phase 3 trial, 72 weeks, 16 Japanese research centers.
- Dose
- Oral orforglipron 6 mg, 12 mg or 36 mg once daily, or placebo.
- Primary result
- Bodyweight change: -5.9% (6 mg), -8.7% (12 mg), -7.9% (36 mg) vs -0.6% placebo at week 72.
- Secondary
- At least 5% weight loss: 45.6% (6 mg), 60.8% (12 mg), 58.8% (36 mg) vs 15.2% placebo. 90% completed the study.
- Funding / conflicts
- Funded by Eli Lilly and Company. Four authors are Eli Lilly Japan employees and Eli Lilly shareholders; other authors report fees from drug companies including Eli Lilly and Novo Nordisk.
- Date
- Oct 30, 2026